Regulatory and Washington

JUUL Labs on Monday commended Iowa Attorney General Tom Miller for convening an international advisory group consisting of public health and tobacco control experts that will advise the company on how to keep JUUL out of the hands of youth.

The Drug Enforcement Administration has further clarified its stance on the legality of cannabidiol and confirmed that some CBD products are legal to distribute freely throughout the United States and do not fall under the regulations of the Controlled Substances Act, a move that has drawn praise from CBD retailers.

The Senate Finance Committee has passed the Every Prescription Conveyed Securely Act, little more than a month after the House Energy and Commerce Committee passed its House counterpart.

As new and novel tobacco products that appeal to youth continue to hit the market, research shows that tobacco use rates among middle and high school students essentially flattened in 2017 after an encouraging decline from 2015 to 2016, according to the National Youth Tobacco Survey results, released Thursday by the Centers for Disease Control and Prevention.

The U.S. Food and Drug Administration on Wednesday filed a complaint against Innovative BioDefense of Lake Forest, Calif., and Colette Cozean, the company's president and CEO, to prohibit them from selling Zylast topical antiseptics with claims that they are effective against infection by pathogens such as norovirus, rotavirus, flu virus, Methicillin-Resistant Staphylococcus Aureus (MRSA), and Ebola.

New Hampshire has adopted the real-time, stop-sale National Precursor Log Exchange technology, becoming the 35th state to adopt the system used by retailers across the country to help prevent the illegal sale of pseudoephedrine.

The Consumer Healthcare Products Association, a national trade association representing manufacturers and marketers of OTC medicines and dietary supplements, applauded the U.S. House Ways and Means Health Subcommittee for Wednesday’s hearing on the benefits of consumer-directed health plans and submitted a statement reiterating its support of legislation to restore OTC eligibility under tax-preferred healthcare accounts.

The Food and Drug Administration sent Amgen a complete response letter for its Biologics License application for potential Herceptin biosimilar ABP 90.